Please ensure Javascript is enabled for purposes of website accessibility

When Will Pfizer's and Moderna's COVID Vaccines Be Available for Younger Kids?

By Keith Speights - Updated Jun 24, 2021 at 8:05AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

It probably won't be very far in the future.

The COVID-19 vaccine developed by Pfizer (PFE 3.77%) and BioNTech (BNTX 1.11%) is now available to adolescents between the ages of 12 and 15. However, the two companies, along with Moderna (MRNA -0.37%), hope to win authorizations for their vaccines to immunize younger children as well. In this Motley Fool Live video recorded on May 17, healthcare and cannabis bureau chief Corinne Cardina and Motley Fool contributor Keith Speights discuss when Pfizer's and Moderna's COVID-19 vaccines might be available to younger kids.

Corinne Cardina: Let's go even younger. What is the status of the under 12 population in terms of clinical trials and when could we expect similar news for babies to 11 years?

Keith Speights: Yeah, so they're making progress on that front as well, Corinne. Pfizer and BioNTech basically are already conducting clinical studies in this younger age group, the companies are evaluating different dosing levels.

They're starting with one-third of the dose that they give to adults and they're trying that out and then ramping it up a little bit. Because the thought is that a lower dose could be just as effective in the younger kids as the full doses with adults.

Pfizer expects to report its results from clinical studies in this younger age range by September so that's coming up pretty quickly. Assuming all goes well, I would think that the vaccine could receive an EUA amendment sometime in the early fall, I would think.

Moderna's running a little behind Pfizer. Like Pfizer, the company is also evaluating lower doses in kids. It looks like Moderna's vaccine could be available for younger kids in early '22 based on what I'm seeing. Maybe a little sooner than that.

I think we're going to realistically be seeing these vaccines -- the first one be available for the younger age range sometime later this year, and then the second vaccine probably being available sometime early next year.

Corinne Cardina owns shares of Moderna Inc. Keith Speights owns shares of Pfizer. The Motley Fool recommends Moderna Inc. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Pfizer Inc. Stock Quote
Pfizer Inc.
PFE
$50.11 (3.77%) $1.82
Moderna, Inc. Stock Quote
Moderna, Inc.
MRNA
$171.18 (-0.37%) $0.63
BioNTech SE Stock Quote
BioNTech SE
BNTX
$160.35 (1.11%) $1.76

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
400%
 
S&P 500 Returns
128%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 08/14/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.